Half year report to 30 June released. Link below. Projections suggest cash flow positive by end of 2016. Capital raising coming. Also coming 3 new products in the pipeline.

Interesting that artemisia annua is the basis for the malaria treatment which has just got a Nobel prize. PIL was pursuing the malaria angle when they found that folk in those trials got arthritis relief.

Extract

Sales in New Zealand are exceeding budgets and growing. There has been
a large increase in the average monthly sales since May 2015 when the company
announced the positive preliminary clinical trial findings. Sales of the company’s
flagship product Arthrem® have increased by more than 150% compared to the
previous 12 month average monthly sales.
The company has had some sales success in the United States but is awaiting
publication of its clinical trial results before embarking on a concerted public relations
campaign. The US e-commerce platform is fully operational and a soft launch in June
exceeded budget. Promisia is testing various offerings in an effort to determine the
most effective sales strategy. The US market represents the greatest opportunity
for Promisia to increase revenues. The market is approximately 90 times larger
than New Zealand and it carries with it a higher level of discretionary spending.

http://www.promisia.com/financial-reports.